The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit research and development organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable access.
The World Health Organization (WHO) and DNDi launched GARDP in May 2016. DNDi thereafter incubated GARDP by providing the initial governance, scientific environment and infrastructure, as well as support for resource mobilization, communication, finance, and human resources.
During this incubation phase, GARDP built a skilled team and formed a Board of Directors with leading international experts. GARDP also formed numerous partnerships with industry, academia, and research institutions in support of its clinical programmes to develop antibiotics for drug-resistant infections for children, newborns with sepsis, and sexually-transmitted infections.
In July 2018, GARDP became an independent legal entity, which became operational in January 2019 following the successful three-year incubation.
